Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Immunodiagnostic Systems Says Targets Are "Challenging But Achievable"

Thu, 26th Jul 2018 13:47

LONDON (Alliance News) - Immunodiagnostic Systems Holdings PLC said Thursday that its target to return to revenue growth in the current year is a "challenging but achievable task", as it posted first quarter revenue decline.

Revenue for the first quarter of the year to June 30, was down 4% at GBP9.3 million form the year before. On a like-for-like basis first quarter revenue decreased by 3%.

By division, the company's Automated Business saw like-for-like revenue down 8% to GBP5.4 million. Manual Business revenue dropped 7% to GBP3.0 million while Technology Business revenue increased 67% to GBP900,000.

Despite the drop in revenue, the company maintained its guidance of returning to growth within the end of the current financial year.

Immunodiagnostic shares were untraded at 235.00 pence on Thursday.

Related Shares

More News
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

17 May 2021 11:15

AIM WINNERS & LOSERS: Immunodiagnostic surges on PerkinElmer takeover

AIM WINNERS & LOSERS: Immunodiagnostic surges on PerkinElmer takeover

17 May 2021 09:21

Immunodiagnostic Systems agrees GBP110 million bid by US's PerkinElmer

Immunodiagnostic Systems agrees GBP110 million bid by US's PerkinElmer

17 May 2021 08:13

LONDON BRIEFING: Ryanair hopeful for end of curbs, "gamechanger" jet

LONDON BRIEFING: Ryanair hopeful for end of curbs, "gamechanger" jet

17 May 2021 07:52

LONDON MARKET PRE-OPEN: Vistry raises profit guidance on strong demand

LONDON MARKET PRE-OPEN: Vistry raises profit guidance on strong demand

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.